XML 21 R9.htm IDEA: XBRL DOCUMENT
v3.19.2

License, Clinical Trial and Sponsored Research Agreements | 6 Months Ended
--- | ---
Jun. 30, 2019
License, Clinical Trial and Sponsored Research Agreements |
License, Clinical Trial and Sponsored Research Agreements | Note 3 - License, Clinical Trial and Sponsored Research Agreements Research and Development Expenses - All Licenses For the three and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for licenses acquired:
|  | For the three months ended June 30, |  | For the six months ended June 30,
($ in thousands) |  | 2019 |  | 2018 |  | 2019 |  | 2018
City of Hope |  |  |  |  |  |  |  |  |  |  |  |
CD123 |  | $ | — |  | $ | — |  | $ | 250 |  | $ | —
CS1 |  |  | 200 |  |  | — |  |  | 200 |  |  | —
Manufacturing |  |  | — |  |  | — |  |  | — |  |  | 75
Nationwide Children's Hospital - C134 |  |  | — |  |  | — |  |  | 200 |  |  | —
Total |  | $ | 200 |  | $ | — |  | $ | 650 |  | $ | 75
License Agreements City of Hope CS1 License (MB-104) In May 2017, the Company entered into an exclusive license agreement with the City of Hope National Medical Center (“COH”) for the use of CS1-specific chimeric antigen receptor (“CAR”) engineered T cell (“CAR T”) technology. Pursuant to this agreement, the Company paid an upfront fee of $0.6 million and pays an annual maintenance fee of $50,000. Additional payments are due for the achievement of ten development milestones totaling $14.9 million and royalty payments in the mid-single digits are due on net sales of licensed products. In May 2019 the Company expensed a non-refundable milestone payment of $0.2 million upon the first patient dosed in a Phase 1 clinical study of CS1. CD123 License (MB-102) In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with the COH to acquire intellectual property rights pertaining to CD123-specific CAR T technology. Pursuant to this agreement, the Company and COH acknowledged that an upfront fee was previously paid. In addition, COH is eligible to receive an annual maintenance fee of $25,000 and milestone payments totaling $14.5 million upon the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. In the first quarter of 2019, the Company expensed a non-refundable milestone payment of $0.3 million upon the twelfth patient dosed in a Phase 1 clinical study of CD123. Nationwide Children’s Hospital In February 2019, Mustang announced that it partnered and entered into an exclusive worldwide license agreement with Nationwide Children’s Hospital (“Nationwide”) to develop their C134 oncolytic virus (MB‑108) for the treatment of glioblastoma multiforme (“GBM”). Mustang intends to combine MB‑108 with MB‑101 (IL13Rα2‑specific CAR T) to potentially enhance efficacy in treating GBM. The Company paid $0.2 million in consideration for the license to exclusive, worldwide rights to develop and commercialize products that incorporate data, know-how and/or MB‑108 that were developed at Nationwide. Additional payments are due to Nationwide upon achievement of development and commercialization milestones totaling $152.8 million. Royalty payments in the low-single digits are due on net sales of licensed products. Research and Development Expenses - Sponsored Research and Clinical Trial Agreements For the three and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:
|  | For the three months ended June 30, |  | For the six months ended June 30,
|  | 2019 |  | 2018 |  | 2019 |  | 2018
($ in thousands) |  |  |  |  |  |  |  |  |  |  |  |
City of Hope |  | $ | 500 |  | $ | 500 |  | $ | 1,000 |  | $ | 1,000
City of Hope - CD123 |  |  | 456 |  |  | 114 |  |  | 759 |  |  | 264
City of Hope - IL13Rα2 |  |  | 225 |  |  | 143 |  |  | 567 |  |  | 503
City of Hope - Manufacturing |  |  | 115 |  |  | 115 |  |  | 229 |  |  | 229
Fred Hutch - CD20 |  |  | 374 |  |  | 418 |  |  | 641 |  |  | 684
BIDMC - CRISPR |  |  | — |  |  | — |  |  | 69 |  |  | —
Total |  | $ | 1,670 |  | $ | 1,290 |  | $ | 3,265 |  | $ | 2,680

X
- References No definition available. + Details
Name: | mbio_LicenseAgreementDisclosureAbstract
Namespace Prefix: | mbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of accounting policy for license agreement. + References No definition available. + Details
Name: | mbio_LicenseAgreementDisclosureTextBlock
Namespace Prefix: | mbio_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration